Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat patients with pancreatic cancer.

The Melbourne-based company is focused on developing new approaches for the treatment of cancer and fibrosis, including advancing a pipeline of focal adhesion kinase (FAK) inhibitors such as AMP945.

To view media story please click here.